• On July 10, 2026, Pfizer and Astellas said the FDA approved PADCEV plus Keytruda or Keytruda QLEX as the first platinum‑free neoadjuvant and adjuvant regimen for adult muscle‑invasive bladder cancer patients, regardless of cisplatin eligibility.
• This decision broadens PADCEV’s role from later‑stage disease into earlier, curative‑intent treatment, potentially deepening Pfizer’s presence in bladder cancer care pathways.
• We’ll now examine how this earlier‑stage PADCEV‑Keytruda approval fits into Pfizer’s longer‑term oncology‑led investment narrative.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe that management can replace fading COVID and patent‑at‑risk revenues with an oncology‑led portfolio while supporting a high dividend. The new earlier‑stage PADCEV plus Keytruda approval reinforces that oncology story and strengthens a key near‑term catalyst in cancer, but it does not change the biggest overhang of patent expirations, pricing pressure and earnings forecasts that still point to declining profit over the next few years.

Among recent developments, the July 10 PADCEV label expansion itself is most relevant, because it builds on earlier approvals that had already pushed PADCEV plus Keytruda into later‑stage urothelial cancer and cisplatin‑ineligible MIBC. Together, these indications underline why some analysts see oncology as one of the few areas offsetting headwinds from a 7.09% dividend that is not fully covered by earnings and ongoing concerns about patent cliffs and tougher drug pricing policies.

Yet investors should also be aware that, despite this oncology progress, the combination of patent expirations and a dividend not fully covered by earnings could...

Pfizer's narrative projects $54.9 billion revenue and $9.2 billion earnings by 2029.

Uncover how Pfizer's forecasts yield a $29.19 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some analysts were already optimistic that oncology wins like this could help lift Pfizer toward about US$57.5 billion in revenue and US$11.3 billion in earnings by 2029, which is far more upbeat than consensus, so if you are weighing PADCEV’s new role you should recognize how sharply views can diverge and consider how this approval might shift both the bullish and more cautious narratives.

Explore 21 other fair value estimates on Pfizer - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.